Customize your JAMA Network experience by selecting one or more topics from the list below.
Georgitis JW. Nasal Atropine Sulfate: Efficacy and Safety of 0.050% and 0.075% Solutions for Severe Rhinorrhea. Arch Otolaryngol Head Neck Surg. 1998;124(8):916–920. doi:10.1001/archotol.124.8.916
Anticholinergic agents, specifically the quaternary salt of atropine, are currently being recommended for chronic rhinitis and the common cold.
To evaluate the efficacy and safety of 50- and 75-µg doses of atropine sulfate as a nasal spray in perennial allergic rhinitis.
A placebo-controlled, double-blind study compared 2 doses of atropine nasal spray given 4 times daily for 2 weeks to 45 patients with perennial allergic rhinitis after a 2-week baseline period.
Both concentrations of atropine nasal spray improved the severity of rhinorrhea and postnasal drip (P<.001) as reported by patients and physicians. The duration of action in reducing rhinorrhea and postnasal drip for atropine was 2 to 3 hours, compared with less than 1 hour for placebo (P<.01). No difference was noted in efficacy between the 2 atropine doses nor in frequency of adverse events with atropine nasal spray and placebo.
Atropine sulfate, 50 or 75 µg 4 times daily, is effective in reducing rhinorrhea and postnasal drip within 2 weeks and may be an alternative therapy for the rhinorrhea component of rhinitis.
Create a personal account or sign in to: